Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1093/cid/ciaa587 http://scihub22266oqcxt.onion/10.1093/cid/ciaa587 32409832!7239253!32409832     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=32409832&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Clin+Infect+Dis 2020 ; 71 (16): 2191-2194 Nephropedia Template TP {{tp|p=32409832|t=2020. COVID-19 Pandemic: Time to Revive the Cyclophilin Inhibitor Alisporivir |pdf=|usr=}}{{32409832}} gab.com Text COVID-19 Pandemic: Time to Revive the Cyclophilin Inhibitor Alisporivir JO: Clin Infect Dis http://www.kidney.de/pget.php?&tw=1&pmid=32409832 #FOAvip December 2019 saw the emergence of a new epidemic of pneumonia of varying severity, called coronavirus disease 2019 (COVID-19), caused by a newly identified coronavirus, severe acute respiratory syndrome coronavirus (SARS-CoV-2). No therapeutic option is available to treat this infection that has already killed > 310 000 people worldwide. This Viewpoint summarizes the strong scientific arguments supporting the use of alisporivir, a nonimmunosuppressive analogue of cyclosporine A with potent cyclophilin inhibition properties that has reached phase 3 clinical development, for the treatment of COVID-19. They include the strong cyclophilin dependency of the life cycle of many coronaviruses, including severe acute respiratory syndrome coronavirus and Middle East respiratory syndrome coronavirus, and preclinical data showing strong antiviral and cytoprotective properties of alisporivir in various models of coronavirus infection, including SARS-CoV-2. Alisporivir should be tested without delay on both virological and clinical endpoints in patients with or at risk of severe forms of SARS-CoV-2 infection. Twit Text FOAVip COVID-19 Pandemic: Time to Revive the Cyclophilin Inhibitor Alisporivir ????Clin Infect Dis http://www.kidney.de/pget.php?&tw=1&pmid=32409832 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32409832 #FOAvip English Wikipedia <ref>{{Cite pmid|32409832}}</ref> COVID-19 Pandemic: Time to Revive the Cyclophilin Inhibitor Alisporivir #MMPMID32409832 Pawlotsky JM Clin Infect Dis 2020[Nov]; 71 (16): 2191-2194 PMID32409832show ga December 2019 saw the emergence of a new epidemic of pneumonia of varying severity, called coronavirus disease 2019 (COVID-19), caused by a newly identified coronavirus, severe acute respiratory syndrome coronavirus (SARS-CoV-2). No therapeutic option is available to treat this infection that has already killed > 310 000 people worldwide. This Viewpoint summarizes the strong scientific arguments supporting the use of alisporivir, a nonimmunosuppressive analogue of cyclosporine A with potent cyclophilin inhibition properties that has reached phase 3 clinical development, for the treatment of COVID-19. They include the strong cyclophilin dependency of the life cycle of many coronaviruses, including severe acute respiratory syndrome coronavirus and Middle East respiratory syndrome coronavirus, and preclinical data showing strong antiviral and cytoprotective properties of alisporivir in various models of coronavirus infection, including SARS-CoV-2. Alisporivir should be tested without delay on both virological and clinical endpoints in patients with or at risk of severe forms of SARS-CoV-2 infection. |*COVID-19 Drug Treatment[MESH] |Animals[MESH] |Antiviral Agents/*therapeutic use[MESH] |COVID-19/epidemiology[MESH] |Clinical Trials as Topic[MESH] |Cyclophilins/*antagonists & inhibitors[MESH] |Cyclosporine/*therapeutic use[MESH] |Disease Models, Animal[MESH] |Humans[MESH] |Mice[MESH] |Rats[MESH]COVID-19 Pandemic: Time to Revive the Cyclophilin Inhibitor Alisporivi(epmc).pdf DeepDyve Pubget Overpricing